Melanotan 2 for women: Frequently asked questions

This represents a known pharmacological effect, not an adverse event. Documentation and dose adjustment address the concern. Approximately 10–15% of female subjects report sexual arousal effects they find disruptive or inappropriate for their research participation context. The effect is dose-dependent and mediated through MC4R activation in ventral tegmental area dopaminergic neurons. Reducing dose by 25–50% typically decreases arousal intensity while maintaining melanogenesis or appetite endpoints. The effect dissipates within 4–6 hours of peak plasma concentration, so timing administration relative to daily schedule provides another management strategy.

Reduce the dose by 50% and maintain that level for 5–7 days before attempting re-escalation. Most subjects develop tolerance through MC4R receptor desensitization within 3–5 administrations, but approximately 15–20% demonstrate persistent nausea sensitivity. The mechanism likely involves individual variation in area postrema MC4R density or genetic polymorphisms affecting receptor internalization rates. Administering doses with food (despite slower absorption kinetics) reduces nausea intensity in approximately 60% of sensitive subjects. If nausea persists at doses below 0.5mg, the subject likely represents a non-responder phenotype unsuitable for protocols requiring higher doses.

Discontinue peptide administration immediately and document exposure timing relative to conception. No human reproductive toxicity data exists, creating an evidence gap that precludes informed risk assessment. Animal developmental toxicity studies at 100× human-equivalent doses showed no teratogenic effects, but melanocortin receptors play documented roles in fetal development. The peptide's 33-minute half-life means clearance occurs within hours, but melanogenesis effects persist for weeks. Case reporting to institutional review boards is essential for building the safety database this research area completely lacks.

Immediate dermatological evaluation with dermatoscopy is required. Protocol continuation should pause pending assessment. While uniform darkening of all pigmented lesions is expected, asymmetric changes, border irregularity, or diameter increase beyond proportional darkening suggests possible melanocytic dysplasia unrelated to peptide use. Melanotan-2 does not cause melanoma, but it makes visual surveillance substantially more difficult by altering the baseline appearance of concerning lesions. Any morphological change beyond color intensification warrants biopsy consideration. Research protocols should exclude subjects with personal or family history of melanoma or dysplastic nevus syndrome.

Stop injections immediately and monitor blood pressure twice daily for 72 hours. MT2-induced hypertension typically resolves within 24–48 hours as receptor occupancy declines, but sustained elevation beyond 72 hours suggests unmasking of underlying hypertension that requires medical evaluation. Restarting at 50% of the previous dose may allow tanning without cardiovascular effects, but only under prescriber supervision with baseline ECG and lipid panel assessment. Women over 40 should not resume MT2 if systolic blood pressure exceeded 160 mmHg or diastolic exceeded 100 mmHg during use.

Discard it immediately. Do not inject. Properly reconstituted melanotan-2 is clear and colorless; cloudiness indicates bacterial contamination or peptide aggregation from improper storage. Aggregated peptides lose biological activity and can trigger immune responses ranging from injection-site reactions to systemic hypersensitivity. The correct reconstitution process uses bacteriostatic water added slowly down the vial wall (never shaken), stored at 2–8°C, and used within 28 days. Any temperature excursion above 8°C for more than 4 hours causes irreversible protein denaturation.

Consider topical melanocortin analogs or professionally applied spray tanning instead. Afamelanotide (Scenesse) is an FDA-approved MC1R-selective agonist that provides melanogenesis without MC4R cardiovascular activation, but it's approved only for erythropoietic protoporphyria treatment and requires subcutaneous implant administration. DHA-based self-tanners create pigmentation through non-enzymatic glycation of skin proteins. Zero systemic absorption, zero cardiovascular effects, results in 4–6 hours. For women over 40 seeking skin tone enhancement, the cardiovascular risks of systemic melanocortin agonists outweigh cosmetic benefits in nearly all cases.